Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

The androstenedione derivative, exemestane (FCE 24304), is a new orally active irreversible aromatase inhibitor. Fifty-six post-menopausal advanced breast cancer patients entered this study to evaluate the activity of four low exemestane doses in reducing oestrogen levels. The drug's tolerabili...

Descripción completa

Detalles Bibliográficos
Autores principales: Zilembo, N., Noberasco, C., Bajetta, E., Martinetti, A., Mariani, L., Orefice, S., Buzzoni, R., Di Bartolomeo, M., Di Leo, A., Laffranchi, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034036/
https://www.ncbi.nlm.nih.gov/pubmed/7547212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034036/
https://www.ncbi.nlm.nih.gov/pubmed/7547212

Ejemplares similares